

# Jennifer E Hardingham

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1570089/jennifer-e-hardingham-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59  
papers

1,878  
citations

25  
h-index

42  
g-index

60  
ext. papers

2,148  
ext. citations

5.7  
avg, IF

4.45  
L-index

#	Paper	IF	Citations
59	VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.. <i>Scientific Reports</i> , <b>2022</b> , 12, 1238	4.9	1
58	Anti-Angiogenic Properties of Ginsenoside Rg3 Epimers: In Vitro Assessment of Single and Combination Treatments. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
57	Anti-Cancer Effects of an Optimised Combination of Ginsenoside Rg3 Epimers on Triple Negative Breast Cancer Models. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	2
56	Differential antiangiogenic and anticancer activities of the active metabolites of ginsenoside Rg3. <i>Journal of Ginseng Research</i> , <b>2021</b> ,	5.8	1
55	Appendiceal neoplasm incidence and mortality rates are on the rise in Australia. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2021</b> , 15, 203-210	4.2	2
54	Immunohistochemistry features and molecular pathology of appendiceal neoplasms. <i>Critical Reviews in Clinical Laboratory Sciences</i> , <b>2021</b> , 58, 369-384	9.4	1
53	Anti-Angiogenic Properties of Ginsenoside Rg3. <i>Molecules</i> , <b>2020</b> , 25,	4.8	13
52	High preoperative levels of circulating SFRP5 predict better prognosis in colorectal cancer patients. <i>Future Oncology</i> , <b>2020</b> , 16, 2499-2509	3.6	3
51	Combined pharmacological administration of AQP1 ion channel blocker AqB011 and water channel blocker Bacopaside II amplifies inhibition of colon cancer cell migration. <i>Scientific Reports</i> , <b>2019</b> , 9, 12635	4.9	18
50	Bacopasides I and II Act in Synergy to Inhibit the Growth, Migration and Invasion of Breast Cancer Cell Lines. <i>Molecules</i> , <b>2019</b> , 24,	4.8	12
49	Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry. <i>Targeted Oncology</i> , <b>2019</b> , 14, 85-91	5	8
48	Ginsenoside Rg3: Potential Molecular Targets and Therapeutic Indication in Metastatic Breast Cancer. <i>Medicines (Basel, Switzerland)</i> , <b>2019</b> , 6,	4.1	25
47	Bumetanide-Derived Aquaporin 1 Inhibitors, AqB013 and AqB050 Inhibit Tube Formation of Endothelial Cells through Induction of Apoptosis and Impaired Migration In Vitro. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	13
46	Reduced aquaporin-1 transcript expression in colorectal carcinoma is associated with promoter hypermethylation. <i>Epigenetics</i> , <b>2019</b> , 14, 158-170	5.7	7
45	Stereoselective Anti-Cancer Activities of Ginsenoside Rg3 on Triple Negative Breast Cancer Cell Models. <i>Pharmaceuticals</i> , <b>2019</b> , 12,	5.2	20
44	Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer. <i>Journal of Breast Cancer</i> , <b>2019</b> , 22, 341-361	3	26
43	Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 141-148	3.8	11

42	The Purified Extract from the Medicinal Plant , Bacopaside II, Inhibits Growth of Colon Cancer Cells In Vitro by Inducing Cell Cycle Arrest and Apoptosis. <i>Cells</i> , <b>2018</b> , 7,	7.9	31
41	The Aquaporin 1 Inhibitor Bacopaside II Reduces Endothelial Cell Migration and Tubulogenesis and Induces Apoptosis. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	19
40	Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in Wild-Type Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3838-3844	12.9	5
39	Soluble HLA-G is a differential prognostic marker in sequential colorectal cancer disease stages. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 2577-2586	7.5	20
38	High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab. <i>Clinical and Translational Oncology</i> , <b>2017</b> , 19, 718-726	3.6	12
37	Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 2183-2191	7.5	20
36	Findings in young adults at colonoscopy from a hospital service database audit. <i>BMC Gastroenterology</i> , <b>2017</b> , 17, 56	3	12
35	Role of Aquaporin 1 Signalling in Cancer Development and Progression. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	58
34	A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 643-643	2.2	0
33	Differential Inhibition of Water and Ion Channel Activities of Mammalian Aquaporin-1 by Two Structurally Related Bacopaside Compounds Derived from the Medicinal Plant <i>Bacopa monnieri</i> . <i>Molecular Pharmacology</i> , <b>2016</b> , 90, 496-507	4.3	38
32	Pharmacological blockade of aquaporin-1 water channel by AqB013 restricts migration and invasiveness of colon cancer cells and prevents endothelial tube formation in vitro. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2016</b> , 35, 36	12.8	45
31	Rising incidence of early-onset colorectal cancer in Australia over two decades: report and review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 6-13	4	82
30	Detection and Clinical Significance of Circulating Tumor Cells in Colorectal Cancer--20 Years of Progress. <i>Molecular Medicine</i> , <b>2015</b> , 21 Suppl 1, S25-31	6.2	90
29	Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. <i>British Journal of Cancer</i> , <b>2015</b> , 112, 963-70	8.7	31
28	Nanostructured polystyrene well plates allow unbiased high-throughput characterization of circulating tumor cells. <i>ACS Applied Materials &amp; Interfaces</i> , <b>2014</b> , 6, 20828-36	9.5	26
27	Can we accurately report PTEN status in advanced colorectal cancer?. <i>BMC Cancer</i> , <b>2014</b> , 14, 128	4.8	9
26	Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 731-41	7.5	25
25	Predictive biomarkers of response to anti-EGF receptor monoclonal antibody therapies. <i>Colorectal Cancer</i> , <b>2014</b> , 3, 223-232	0.8	1

24	Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1506-16	10.3	142
23	Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. <i>Cancer Medicine</i> , <b>2013</b> , 2, 277-85	4.8	28
22	A simple, cost-effective and flexible method for processing of snap-frozen tissue to prepare large amounts of intact RNA using laser microdissection. <i>Biochimie</i> , <b>2012</b> , 94, 2491-7	4.6	9
21	Increased Phospho-Keratin 8 Isoforms in Colorectal Tumors Associated with EGFR Pathway Activation and Reduced Apoptosis <b>2012</b> , 2012, 706545		3
20	Small cell lung cancer: patterns of care and their influence on survival - 25 years experience of a single Australian oncology unit. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2011</b> , 7, 252-7	1.9	4
19	Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels. <i>Clinical Proteomics</i> , <b>2011</b> , 8, 16	5	25
18	Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2675-82	2.2	168
17	Length of lymphangiogenesis in the rectal tissues distal to rectal cancer. <i>Tumor Biology</i> , <b>2010</b> , 31, 667-71	2.9	1
16	Stem cell marker olfactomedin 4: critical appraisal of its characteristics and role in tumorigenesis. <i>Cancer and Metastasis Reviews</i> , <b>2010</b> , 29, 761-75	9.6	47
15	Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 417-23	12.9	105
14	Extent of over-expression of hepatocyte growth factor receptor in colorectal tumours is dependent on the choice of normaliser. <i>Biochemical and Biophysical Research Communications</i> , <b>2006</b> , 341, 1017-21	3.4	6
13	Detection of occult metastasis in lymph nodes from colorectal cancer patients: a multiple-marker reverse transcriptase-polymerase chain reaction study. <i>Diseases of the Colon and Rectum</i> , <b>2004</b> , 47, 679-85	3.1	16
12	Dipeptidase 1: a candidate tumor-specific molecular marker in colorectal carcinoma. <i>Cancer Letters</i> , <b>2004</b> , 209, 67-74	9.9	26
11	Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer. <i>BMC Molecular Biology</i> , <b>2001</b> , 2, 15	4.5	83
10	Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. <i>International Journal of Cancer</i> , <b>2000</b> , 89, 8-13	7.5	125
9	Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. <i>International Journal of Cancer</i> , <b>2000</b> , 89, 8-13	7.5	45
8	Somatic mutations, acetylator status, and prognosis in colorectal cancer. <i>Gut</i> , <b>1998</b> , 42, 669-72	19.2	28
7	Detection of Circulating Tumor Cells Using Immunobead-PCR. <i>Methods in Molecular Medicine</i> , <b>1998</b> , 16, 225-32		1

6	Immunobead RT-PCR: a sensitive method for detection of circulating tumor cells. <i>BioTechniques</i> , <b>1997</b> , 22, 100-5	2.5	51
5	Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , <b>1995</b> , 13, 1073-9	2.2	54
4	Detection of Circulating Tumor Cells in Colorectal Cancer by Immunobead-PCR Is a Sensitive Prognostic Marker for Relapse of Disease. <i>Molecular Medicine</i> , <b>1995</b> , 1, 789-794	6.2	98
3	Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease. <i>Molecular Medicine</i> , <b>1995</b> , 1, 789-94	6.2	27
2	Immunobead-PCR: a technique for the detection of circulating tumor cells using immunomagnetic beads and the polymerase chain reaction. <i>Cancer Research</i> , <b>1993</b> , 53, 3455-8	10.1	83
1	A rare translocation (4;11)(q21;p14-15) in an acute lymphoblastic leukemia expressing T-cell and myeloid markers. <i>Cancer Genetics and Cytogenetics</i> , <b>1991</b> , 56, 255-62		12